Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma

Frank C. Passero, Dashnamoorthy Ravi, J. Tyson McDonald, Afshin Beheshti, Kevin A. David, Andrew M. Evens

Research output: Contribution to journalArticle

Abstract

Ixazomib activity and transcriptomic analyses previously established in T cell (TCL) and Hodgkin (HL) lymphoma models predicted synergistic activity for histone deacetylase (HDAC) inhibitory combination. In this present study, we determined the mechanistic basis for ixazomib combination with the HDAC inhibitor, belinostat, in HL and TCL cells lines (ixazomib-sensitive/resistant clones) and primary tumour cells. In ixazomib-treated TCL and HL cells, transient inhibition followed by full recovery of proteasomal activity observed was accompanied by induction of proteasomal gene expression with NFE2L2 (also termed NRF2) as a prominent upstream regulator. Downregulation of both NFE2L2 and proteasomal gene expression (validated by quantitative real time polymerase chain reaction) occurred with belinostat treatment in Jurkat and L428 cells. In addition, CRISPR/Cas9 mediated knockdown of NFE2L2 in Jurkat cells resulted in a significant decrease in cell viability with ixazomib compared with untreated control cells. Using transcriptomic and proteasomal activity evaluation of ixazomib, belinostat, or ixazomib + belinostat treated cells, we observed that NFE2L2, proteasome gene expression and functional recovery were abrogated by ixazomib + belinostat combination, resulting in synergistic drug activity in ixazomib-sensitive and -resistant cell lines and primary cells. Altogether, these results suggest that the synergistic activity of ixazomib + belinostat is mediated via inhibition NFE2L2-dependent proteasomal recovery and extended proteasomal inhibition culminating in increased cell death.

Original languageEnglish (US)
Pages (from-to)295-308
Number of pages14
JournalBritish Journal of Haematology
Volume188
Issue number2
DOIs
StatePublished - Jan 1 2020

Fingerprint

T-Cell Lymphoma
Hodgkin Disease
Apoptosis
Therapeutics
Jurkat Cells
T-Lymphocytes
Gene Expression
Clustered Regularly Interspaced Short Palindromic Repeats
ixazomib
belinostat
Cell Line
Histone Deacetylase Inhibitors
Histone Deacetylases
Proteasome Endopeptidase Complex
Real-Time Polymerase Chain Reaction
Cell Survival
Cell Death
Down-Regulation
Clone Cells

All Science Journal Classification (ASJC) codes

  • Hematology

Keywords

  • HDAC inhibition
  • NFE2L2
  • lymphoma
  • proteasomal inhibition
  • systems biology

Cite this

Passero, Frank C. ; Ravi, Dashnamoorthy ; McDonald, J. Tyson ; Beheshti, Afshin ; David, Kevin A. ; Evens, Andrew M. / Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma. In: British Journal of Haematology. 2020 ; Vol. 188, No. 2. pp. 295-308.
@article{3cbec9965a4f47c988d9b15f6d90610f,
title = "Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma",
abstract = "Ixazomib activity and transcriptomic analyses previously established in T cell (TCL) and Hodgkin (HL) lymphoma models predicted synergistic activity for histone deacetylase (HDAC) inhibitory combination. In this present study, we determined the mechanistic basis for ixazomib combination with the HDAC inhibitor, belinostat, in HL and TCL cells lines (ixazomib-sensitive/resistant clones) and primary tumour cells. In ixazomib-treated TCL and HL cells, transient inhibition followed by full recovery of proteasomal activity observed was accompanied by induction of proteasomal gene expression with NFE2L2 (also termed NRF2) as a prominent upstream regulator. Downregulation of both NFE2L2 and proteasomal gene expression (validated by quantitative real time polymerase chain reaction) occurred with belinostat treatment in Jurkat and L428 cells. In addition, CRISPR/Cas9 mediated knockdown of NFE2L2 in Jurkat cells resulted in a significant decrease in cell viability with ixazomib compared with untreated control cells. Using transcriptomic and proteasomal activity evaluation of ixazomib, belinostat, or ixazomib + belinostat treated cells, we observed that NFE2L2, proteasome gene expression and functional recovery were abrogated by ixazomib + belinostat combination, resulting in synergistic drug activity in ixazomib-sensitive and -resistant cell lines and primary cells. Altogether, these results suggest that the synergistic activity of ixazomib + belinostat is mediated via inhibition NFE2L2-dependent proteasomal recovery and extended proteasomal inhibition culminating in increased cell death.",
keywords = "HDAC inhibition, NFE2L2, lymphoma, proteasomal inhibition, systems biology",
author = "Passero, {Frank C.} and Dashnamoorthy Ravi and McDonald, {J. Tyson} and Afshin Beheshti and David, {Kevin A.} and Evens, {Andrew M.}",
year = "2020",
month = "1",
day = "1",
doi = "10.1111/bjh.16160",
language = "English (US)",
volume = "188",
pages = "295--308",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma. / Passero, Frank C.; Ravi, Dashnamoorthy; McDonald, J. Tyson; Beheshti, Afshin; David, Kevin A.; Evens, Andrew M.

In: British Journal of Haematology, Vol. 188, No. 2, 01.01.2020, p. 295-308.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma

AU - Passero, Frank C.

AU - Ravi, Dashnamoorthy

AU - McDonald, J. Tyson

AU - Beheshti, Afshin

AU - David, Kevin A.

AU - Evens, Andrew M.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Ixazomib activity and transcriptomic analyses previously established in T cell (TCL) and Hodgkin (HL) lymphoma models predicted synergistic activity for histone deacetylase (HDAC) inhibitory combination. In this present study, we determined the mechanistic basis for ixazomib combination with the HDAC inhibitor, belinostat, in HL and TCL cells lines (ixazomib-sensitive/resistant clones) and primary tumour cells. In ixazomib-treated TCL and HL cells, transient inhibition followed by full recovery of proteasomal activity observed was accompanied by induction of proteasomal gene expression with NFE2L2 (also termed NRF2) as a prominent upstream regulator. Downregulation of both NFE2L2 and proteasomal gene expression (validated by quantitative real time polymerase chain reaction) occurred with belinostat treatment in Jurkat and L428 cells. In addition, CRISPR/Cas9 mediated knockdown of NFE2L2 in Jurkat cells resulted in a significant decrease in cell viability with ixazomib compared with untreated control cells. Using transcriptomic and proteasomal activity evaluation of ixazomib, belinostat, or ixazomib + belinostat treated cells, we observed that NFE2L2, proteasome gene expression and functional recovery were abrogated by ixazomib + belinostat combination, resulting in synergistic drug activity in ixazomib-sensitive and -resistant cell lines and primary cells. Altogether, these results suggest that the synergistic activity of ixazomib + belinostat is mediated via inhibition NFE2L2-dependent proteasomal recovery and extended proteasomal inhibition culminating in increased cell death.

AB - Ixazomib activity and transcriptomic analyses previously established in T cell (TCL) and Hodgkin (HL) lymphoma models predicted synergistic activity for histone deacetylase (HDAC) inhibitory combination. In this present study, we determined the mechanistic basis for ixazomib combination with the HDAC inhibitor, belinostat, in HL and TCL cells lines (ixazomib-sensitive/resistant clones) and primary tumour cells. In ixazomib-treated TCL and HL cells, transient inhibition followed by full recovery of proteasomal activity observed was accompanied by induction of proteasomal gene expression with NFE2L2 (also termed NRF2) as a prominent upstream regulator. Downregulation of both NFE2L2 and proteasomal gene expression (validated by quantitative real time polymerase chain reaction) occurred with belinostat treatment in Jurkat and L428 cells. In addition, CRISPR/Cas9 mediated knockdown of NFE2L2 in Jurkat cells resulted in a significant decrease in cell viability with ixazomib compared with untreated control cells. Using transcriptomic and proteasomal activity evaluation of ixazomib, belinostat, or ixazomib + belinostat treated cells, we observed that NFE2L2, proteasome gene expression and functional recovery were abrogated by ixazomib + belinostat combination, resulting in synergistic drug activity in ixazomib-sensitive and -resistant cell lines and primary cells. Altogether, these results suggest that the synergistic activity of ixazomib + belinostat is mediated via inhibition NFE2L2-dependent proteasomal recovery and extended proteasomal inhibition culminating in increased cell death.

KW - HDAC inhibition

KW - NFE2L2

KW - lymphoma

KW - proteasomal inhibition

KW - systems biology

UR - http://www.scopus.com/inward/record.url?scp=85071618675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071618675&partnerID=8YFLogxK

U2 - 10.1111/bjh.16160

DO - 10.1111/bjh.16160

M3 - Article

C2 - 31452195

AN - SCOPUS:85071618675

VL - 188

SP - 295

EP - 308

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -